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CD8+ T cell-mediated specificity depends on the recognition of the MHC class I – epitope complexes 
at the cell surface. These epitopes are mainly produced upon the degradation of proteins by the 
proteasome, generating fragments of the original sequence. However, it is now clear that proteasome 
can produce a significant portion of epitopes by reshuffling the antigen sequence, thus expanding the 
potential antigenic repertoire. MHC class I-restricted spliced epitopes have been described in tumors 
and infections, suggesting an unpredicted relevance of these peculiar peptides. Here, we review 
current knowledge about proteasome-catalyzed peptide splicing, the emerging rules of this process, 
and the potential implications for our understanding and therapeutic use of CD8+ T cells, as well as 
mechanisms generating other non-canonical antigenic epitopes targeted by T cell response.  
 
The unpredicted frequency of proteasome-generated antigenic spliced peptides 
CD8+ T cell specificity is achieved through the recognition by the T cell receptor (TcR) of peptides 
presented in the cleft of major histocompatibility complex class I (MHC-I; see Glossary) molecules. 
The process of antigen presentation, from the original protein to the surface display of MHC-I 
molecule, has been the focus of intense studies. Since more than two decades, the proteasome is 
known to be the main protease responsible for the generation of the vast majority of peptides that are 
bound to the MHC-I cleft at the cell surface (Box 1). This macromolecular enzyme plays a critical role 
in protein homeostasis in all cells. However, each cell type can express different proteasome isoforms, 
which preferentially regulate specific pathways. For instance, the proteasome isoform expressed in 
immune cells or upon inflammation, i.e. the immunoproteasome, was initially thought to be specialized 
only in epitope generation, although later it became evident that this proteasome isoform is involved in 
several other inflammatory processes [1]. Another example is represented by the thymoproteasome, 
which impinges upon the mouse CD8+ T cell repertoire by generating the immunopeptidome of the 
cortical thymic epithelial cells (cTECs), thereby regulating the thymocytes’ positive selection, [2-5] 
(Box 2). Until 2004, all MHC-I-restricted epitopes known to the scientific community were directly 
derived from their corresponding antigen sequences, and, when being generated by proteasome, they 
were products of canonical peptide-bond hydrolysis. In 2004 however, two groups identified two 
epitopes, whose sequence was the fusion of two non-continuous segments of the tumor-associated 
glycoprotein-100 (gp100) or the fibroblast grow factor-5 (FGF-5) antigens carried out through 
proteasome-catalyzed peptide splicing (PCPS) [6-8]. In the following decade, the pioneering work 
of Vigneron, Van den Eynde and colleagues [9-11] led to the identification of only a few other 
proteasome-generated spliced epitopes (Table 1). Therefore, immunologists tagged PCPS as a rare 
event of marginal immunological relevance. The identification of this handful of spliced epitopes was 
possible because of the availability of tumor-infiltrating CD8+ T lymphocytes (TILs) specific for the 
spliced epitopes. Conversely, other researchers developed reverse-immunology and bioinformatics 
approaches combined with mass spectrometry and database search strategies for the systematic 
identification of spliced peptides generated by proteasome. Novel methods were mandatory since the 
sequences of the spliced peptides were not included in any known proteome database, and the 
enormous number of theoretically possible combinations of peptide fragments that proteasome could 
ligate rendered the known proteomic approaches almost useless. These novel strategies allowed the 
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identification of several spliced peptides produced by proteasome during in vitro digestions of 
synthetic polypeptides [12-16], and the identification of the unforeseen dark side of the MHC-I 
immunopeptidome, i.e. thousands spliced peptides presented at the cells surface by MHC-I molecules 
of human B lymphoblastoid cell lines as well as primary fibroblasts [17].  
The fact that almost one third of the antigenic peptides presented by different cells onto the MHC-I 
molecules are generated by PCPS was certainly surprising and might throw a spanner in the works 
that has important theoretical and therapeutic implications. Can this knowledge perturb our notion of 
self and non-self? How shall we reconsider the models of central and peripheral tolerance? Shall we 
reassess our most innovative strategies for epitope identification and validation used, for instance, for 
anti-cancer immunotherapies? 
Here, we review first the mechanisms and regulation of PCPS, before focusing on its important 
ramifications. 
 
Mechanisms and driving forces of PCPS 
Proteasome-generated spliced peptides can be formed in different ways (Fig. 1A, B). The two splice-
reactants are generated inside the proteasome chamber by cleavage of a single peptide sequence 
(cis PCPS), the excision of the sequence between the two splice-reactants (namely the intervening 
sequence) followed by the ligation of the splice-reactants in normal order, i.e. following the orientation 
from N- to C-terminus of the parental protein (normal cis PCPS), or in the reverse order (reverse cis 
PCPS). Furthermore, PCPS can also occur between two splice-reactants originating from two distinct 
proteins (trans PCPS). Although this occurs in vitro [8, 13, 15], its occurrence in cells is disputable [8]. 
It would however be difficult to reckon an immunological relevance of trans spliced peptides. Indeed, 
two specific antigens should repeatedly enter the proteasome in the same order and the putative 
formation of the trans spliced peptide should occur frequently enough to survive the reduction steps in 
the downstream MHC-I antigen presentation pathway and to trigger an efficient T cell response (Box 
1). This could likely happen only in specific conditions (e.g. between viral antigens during viral 
infection) or in specific cellular compartments and/or macro-complexes, which would favor the reaction 
by molecular crowding of a limited variety of peptides. A similar speculation has been proposed to 
explain the production of hybrid epitopes able to trigger the CD4+ T cell response in type 1 diabetes 
mellitus (T1DM) and generated by the fusion of fragments derived from distinct antigens by an 
unknown enzyme [18-20] (see below). 
Despite the recent observation that PCPS can be carried out by a condensation reaction both in 
vitro (either in a cell-free system or in live cells) [16], the most studied and likely the most predominant 
PCPS mechanism is transpeptidation. According to the model originally proposed by Stroobant and 
colleagues [6] and later confirmed with diverse techniques [9, 13], the reaction starts with the break of 
the peptide-bond between the residue of the N-terminal splice reactant (i.e. the residue P1) and the 
following intervening sequence, and the formation of an acyl-enzyme intermediate between the 
residue P1 and the proteasome’s catalytic Thr1. During the canonical peptide hydrolysis, which 
produces all non-spliced peptides, the acyl-enzyme intermediate would react with a molecule of water 
leading to the release of the N-terminal (non-spliced) peptide fragment. In PCPS, on the contrary, the 
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nucleophilic attack to the acyl-enzyme intermediate is mediated by a C-terminal splice-reactant, 
thereby leading to the ligation between the residue P1 of the N-terminal splice-reactant and the residue 
P1’ of the C-terminal splice-reactant (Fig. 1C). Since during the canonical peptide hydrolysis the 
substrate-binding sites of proteasome catalytic pockets are mandatory requirements for the efficient 
reaction catalyzed by the proteasome Thr1, it has been hypothesized that also in PCPS specific 
substrate binding sites exist [10, 13, 21]. Whether these are the same binding sites used for the 
peptide hydrolysis still needs to be proven.  
The existence of PCPS specific binding sites is, however, supported by preliminary evidences that 
PCPS is a finely tuned mechanism rather than a random process. In fact, the formation of given 
spliced peptides is more efficient when the splice-reactants have specific sequence characteristics 
[15] and the substrate’s amino acid residues frequently used by proteasome for peptide hydrolysis are 
not those most frequently used for PCPS [13]. For one specific spliced epitope, the minimal length of 
the splice-reactant was shown to be 3 residues [10], although for other spliced peptides a single 
residue could be ligated in a transpeptidation reaction [22]. Furthermore, it has been shown for a 
specific spliced epitope that the longer is the intervening sequence, the less efficiently the spliced 
epitope is generated [8]. In the much larger pool of spliced peptides of the MHC-I immunopeptidomes 
studied so far, however, we do not see a correlation between the intervening sequence length and the 
antigenic spliced peptide frequency, although the method applied did not allow the identification of 
spliced peptides with intervening sequences longer than 20 amino acid residues [17]. 
Regarding the factors ruling PCPS, standard proteasome and immunoproteasome differ in the 
generation of specific spliced peptides [12, 13, 16, 23, 24]. This is not surprising since they have 
distinctive dynamics of the different aspects of their activities [25] (Box 2), although overall qualitative 
and/or quantitative differences of the PCPS carried out by the two isoforms have not been 
demonstrated so far [13]. How proteasome regulators such as 19S and PA28ab affect PCPS is still 
unknown. 
 
Not just few molecules of each proteasome-generated spliced peptide 
For immunologists, PCPS represents a spanner in the works not because of its existence, but 
because of its high frequency. Although the handful of spliced epitopes discovered in the last decade 
was an excellent pioneering work, it had no general consequences in translational medicine. On the 
contrary, the unexpected large variety and the abundance of the self spliced peptides eluted from the 
MHC-I molecules and identified by mass spectrometry - around one third of the immunopeptidome 
variety and one fourth of its abundance [17] – have some practical and theoretical implications. 
Regarding the practical implications, for instance, it will be now harder to annotate peptide sequences 
derived from MHC-I immunopeptidomes without considering spliced peptides. The latter would lead to 
the wrong assignment of 5-10% sequences, depending on the mass spectrometry method used [17]. 
Considering that the MHC-I immunopeptidome analysis is emerging as an extremely helpful tool for 
the identification of epitope targets for anti-cancer immunotherapy [26-28], the implications of PCPS in 
translational research are clear.  
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Regarding the theoretical implications, we have to consider that in immunobiology, quantity matters. 
Quantitative alterations of epitope production dynamics by the proteasome can lead to the complete 
abrogation of the CD8+ T cell response in mouse models [29-32]. Therefore, determining the quantity 
of antigenic spliced peptides exposed to CD8+ T cells by MHC-I molecules is a key element. Our 
quantification of the spliced and non-spliced peptides identified in three MHC-I immunopeptidomes 
was carried out by a label-free strategy based on the intensity of the mass spectrometry ion peak area 
[17]. Although this method is not directly suitable for quantitative comparison of single peptides [13, 
33], it has become well accepted when analyzing large proteomics datasets to compare two groups of 
peptides making use of the law of large numbers [33-35]. Other quantitative methods [36] could be 
used to corroborate our recent results on three MHC-I immunopeptidomes, where spliced peptides 
showed an abundance distribution comparable to non-spliced peptides, although significantly lower 
[17]. A comparable abundance of spliced epitopes vs non-spliced epitopes at the cell surface has also 
been suggested by assays carried out with CD8+ T cell clones specific for either spliced or non-spliced 
epitopes derived from melanoma-associated antigens [16]. In our experience, the latter strategy is 
more sensitive than modern mass spectrometry approaches - despite their sensational progresses in 
terms of accuracy and sensitivity obtained in the last years [37] – and could provide direct indications 
about the spliced peptides’ immunogenicity. Nonetheless, the isolation of specific CD8+ T cell clones is 
laborious and thus impractical for a system-wide analysis. 
An alternative strategy could be the investigation of PCPS in vitro using purified proteasome and 
synthetic polypeptide substrates, which would in principle allow the quantification of a large number of 
spliced and non-spliced peptide products. Absolute quantification of the peptide products can be done 
through different mass spectrometry-based strategies [13, 37] and a correlation of quantitative 
analyses of proteasome-mediated digestions in cell-free systems with data obtained in cell culture and 
in vivo has been extensively reported [16, 23, 24, 31, 38-43]. The few in vitro studies on PCPS 
conducted so far were carried out with less informative mass spectrometry methods [13, 15] and we 
reckon that the use of more sensitive and accurate mass spectrometers will significantly enlarge our 
horizon about the frequency, relevance and characteristics of PCPS. 
 
Proteasome-generated spliced epitopes derived from tumor-associated antigens 
All six spliced epitopes validated so far in a human system derive from tumor-associated antigens 
(Table 1). For all of these spliced epitopes, human TILs or specific CD8+ T cell clones have been 
isolated. Furthermore, a natural response of memory T cells derived from the peripheral blood of 
melanoma patients against autologous cells presenting spliced epitopes derived from the well-known 
melanoma-associated antigen gp100 – namely gp10047-52/40-42 or gp100195-202/192 – has been described 
[16].  
In addition, the adoptive transfer of a TIL clone specific for the spliced epitope tyrosinase368-373/336-340 
into the autologous melanoma patient was followed by tumor regression [44]. In nonobese 
diabetic/severe combined immunodeficient mice (NOD/SCID), a CD8+ T cell clone specific for  
SP110296-301/286-289 inhibited engraftment of human acute myelogenous leukemia cells [45]. 
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Although these studies all indicate that spliced epitopes could be useful targets for anti-cancer 
immunotherapies, the dimension of the MHC-I spliced immunopeptidome of tumor cells still needs to 
be determined. This is a critical aspect, which might have a significant impact on the most innovative 
anti-cancer immunotherapies such as adoptive T cell therapies (ATTs). The latter can use TILs, or 
autologous CD8+ T cells expressing specific TCRs, as effectors for the recognition and elimination of 
cancer cells [46]. A significant determinant of the efficacy of ATTs resides in the identification of the 
“best” tumor antigens. Ideal targets are epitopes carrying driver somatic mutations, both because they 
represent tumor-specific neoantigens and because they are not easily lost by the tumor, since those 
mutations are involved in the process of malignant transformation [47]. The frequency of these tumor-
specific mutated epitopes is, however, limited by the mutation frequency and by the fact that epitopes 
need to have not only specific motifs for being presented onto MHC-I molecules, but also for passing 
all steps of the antigen presentation pathway (Box 1). As a consequence, the majority of the TILs 
used in clinical trials target tumor-associated rather than tumor-specific antigens, which could in 
consequence trigger undesirable autoimmune reactions [48]. 
In these therapeutic frameworks, the inherent ability of spliced epitopes to extend the antigenic 
landscape and to have potentially extremely large sequence variety could be useful to target tumor-
specific driver mutations that would not be efficiently exposed at the cell surface through non-spliced 
peptides because of incompatibility of the mutated protein sequence with the most common MHC-I 
variants. For instance, the HLA-A*02:01 complex, which is the predominant MHC-I variant in the 
Caucasian population, cannot efficiently present any of the non-spliced peptides that carry some of the 
most common cancer mutations, such as BRAF V600E or KRAS G12D. The latter, on the contrary, can 
be efficiently presented by a non-spliced epitope on the HLA-C*08:02 complex, which can be targeted 
by ATT thereby leading to a complete remission of metastatic colorectal cancer [49]. ATT strategies 
could also target a pool of spliced and non-spliced epitopes, which carry the same driver mutation and 
are presented onto the different MHC-I variants of the patient. This approach would prevent immune-
escaping phenomena like the selective deletion of specific MHC-I-expressing genes [49].  
 
Impact of PCPS during infections and implications for autoimmunity 
CD8+ T cell responses are often mandatory for the clearance of viruses and some other pathogens. 
Furthermore, vaccination trials for Dengue virus, Ebola virus or HIV showed how CD8+ T cell 
activation can play a key role in vaccine development [50-52]. The evidences of the immunogenicity of 
pathogen-derived spliced epitopes during infection are preliminary, and limited so far to the 
intracellular pathogen Listeria monocytogenes [24, 53]. Although the immunological relevance of 
PCPS still needs to be demonstrated on a large scale, some evolutionary advantages of the human 
immune system to target pathogen-derived spliced epitopes can be easily estimated. For instance, 
PCPS significantly enlarges the number of self antigens represented onto the MHC-I molecules at the 
surface of  human B lymphoblastoid cell lines or primary fibroblasts [17]. Similarly, during Listeria 
monocytogenes infection, the phosphatidylcholine-preferring phospholipase C (PlcB) antigen 
elicits a CD8+ T cell response in the C57/BL6 mice only through the presentation of PlcB-derived 
spliced epitopes [54]. The potentially very large variety of the spliced epitopes could also be a useful 
strategy of the immune system to counter-attack mutation-based escape mechanisms of viruses. 
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Indeed, although a mutation can wipe out a single epitope [39], it is less likely to hamper the 
productions of an entire pool of spliced and non-spliced epitopes derived from that portion of the 
antigen.  
However, it is important to consider that the same potentially very large variety of the spliced epitopes 
could influence autoimmune disease etiology. Calis and colleagues [55] estimated that the complete 
sequence overlap between in silico predicted antigenic peptides derived from self (human) or from a 
thousand different viruses is 0.15%, which raises to 0.7% considering the TCR recognition 
degeneracy. Of course, at the time that study did not include spliced peptides. It is easy to predict that 
the overlap between the self and non-self immunopeptidome will dramatically increase by 
encompassing PCPS in the frame. Therefore, theoretically, and depending on how PCPS is carried 
out in the thymus during T cell selection and maturation, we might have two extreme scenarios: either 
a scenario where autoimmunity is epidemic (due to a high overlap between self and non-self) or one 
where many viral antigens are not recognized by peripheral CD8+ T cells, since the corresponding 
TCRs were deleted because of self-recognition, thereby further increasing the so-called holes in the T-
cell repertoire [55]. Understanding why this is not the case requires investigating the link between 
PCPS and antigen presentation in thymus and in periphery. 
At the moment, we can only speculate that PCPS could be involved in the CD8+ T cell-mediated 
immune response against self antigens in those diseases (e.g. myelin in multiple sclerosis or insulin in 
T1DM), where infections have been hypothesized to be involved in the autoimmune pathogenesis [56, 
57].  
 
Hybrid insulin peptides in T1DM 
In multiple sclerosis and T1DM, both CD4+ and CD8+ T cells can target their response toward self 
epitopes presented onto either MHC-I or MHC-II molecules [20, 57-60]. In particular, in T1DM, MHC-II-
restricted and post-translationally spliced epitopes have been recently described. Indeed, two 
independent groups identified hybrid epitopes – i.e. trans spliced epitopes according to our 
nomenclature - that are specifically recognized by CD4+ T cells derived from NOD mice or pancreatic 
islets of patients affected T1DM [18-20]. These hybrid peptides derive from the ligation of few 
sequences of proinsulin to fragments of antigens immunologically relevant in T1DM and packed in the 
secretory vesicles [19, 20]. One CD4+ T cell clone, grown directly from an islet of a T1DM patient, 
recognizes a hybrid peptide derived from the ligation of the insulin C peptide and the insulin A chain. 
This specific epitope could thus be either a trans or a cis spliced peptide, depending on whether it is 
generated after of before the processing of the proinsulin that lead to the formation of the mature 
insulin form [20].  
Because of the targeted-sequence strategy applied in both studies, it is still unclear which is the 
general prevalence of antigenic spliced (both cis and trans) peptides bound to the MHC-II molecules, 
and whether the phenomenon is relevant only for T1DM. Furthermore, it is still unknown which 
enzyme catalyzes their production. Beside the proteasome, other proteases such as Trypsin, Lys-C 
and plant-derived Asparaginyl endoprotease are known to catalyze peptide splicing [61]. In particular, 
the human homologous of the latter protease is also involved in the generation of MHC-II-restricted 
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epitopes [62], and thus it could be a validate candidate for the production of hybrid insulin peptides as 
well as other spliced epitopes presented onto MHC-II complexes.  
 
Concluding remarks 
Bearing in mind the enormous theoretical number of potential combination of splice-reactants, we 
reckon that algorithms estimating the likelihood of a spliced peptide to be generated and to bind to the 
MHC-I molecules will soon be mandatory to investigate the therapeutic applications of PCPS (see 
Outstanding Questions). Although preliminary evidences that PCPS is not a random process are 
encouraging, the pioneering studies on PCPS should be validated on much larger spliced peptide 
pools than the few peptides used as preliminary models. Furthermore, the present MHC-I-peptide 
binding affinity prediction algorithms should be applied carefully to spliced peptides, because they 
have mainly been trained using non-spliced peptide databases, and therefore their use could lead to a 
large number of false negatives [17]. The prediction of immunologically relevant spliced epitopes will 
likely be aided by the analysis of the corresponding antigen characteristics, abundance, turnover and 
translation rate, as these parameters have been correlated with non-spliced immunopeptidomes and 
intracellular proteomes in recent brilliant studies [28, 33, 63-66]. 
Despite the large number of spliced peptides identified in MHC-I immunopeptidomes, and the current 
focus on PCPS, we shall not forget that spliced peptides are only one part of the “non-canonical” 
peptides that are presented onto MHC molecules. In addition to the recent identification of the MHC-II-
restricted hybrid insulin epitopes, which has been here reviewed, there are studies suggesting that a 
sizeable number of MHC-I-restricted antigenic peptides can derive from alternative open reading 
frames [67]. For instance, in T1DM patients, Kracht and colleagues described cytotoxic CD8+ T cells 
capable of killing human b cells by targeting an epitope generated by the usage of an alternative open 
reading frame in the insulin gene [68]. Furthermore, MHC-I-restricted epitopes can originate from non-
coding sequences of the genome [67, 69], and, in principle, also from intergenically spliced chimeric 
RNAs [70].  
Understanding the extension and the immunological relevance of the non-canonical “dark side” of the 
immunopeptidome will be a great challenge with potentially strong translational implications. 
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Figure 1. Proteasome-catalyzed peptide splicing. Spliced peptides can be formed by: (A) cis 
PCPS, i.e. when the two splice-reactants derive from the same polypeptide molecule. The ligation of 
the splice-reactants can occur in normal order, i.e. following the orientation from N- to C-terminus of 
the parental protein (normal cis PCPS), or in the reverse order (reverse cis PCPS); (B) trans PCPS, 
i.e. when the two splice-reactants originate from two distinct protein molecules or two distinct proteins 
[8, 13]. C) The most defined PCPS mechanism is the transpeptidation. According to this model, the 
proteasome’s catalytic Thr1 breaks the peptide bond of the residue (P1) of the protein - thereby 
forming an acyl-enzyme intermediate with the N-terminal splice-reactant, coupled to the release of the 
intervening sequence – and, instead of catalyzing the canonical peptide hydrolysis, it catalyzes the 
ligation between the P1 residue of the N-terminal splice-reactant with the residue P1´ of the C-terminal 
splice-reactant [6, 13]. 
 
 
Table 1. Spliced epitopes derived from tumor-associated antigens 
epitope antigen identification 
method 
notes Reference 





isolated TIL  [7] 
[SLPRGT][STPK] SP110296-301/286-
289 
CD8+ T cell 
clone 
specific CD8+ T cell clone 
inhibited engraftment of 
human acute 
myelogeneous leukemia 




isolated TIL tumor regression in 
melanoma patient after 
ATT with the TIL 
[11] 
[RSYVPLAH][R] gp100195-202/192 isolated TIL natural response of 
memory CD8+ T cells from 
peripheral blood of 
melanoma patients 
[10, 16] 
[QLYPEW][RTK] gp10047-52/40-42 in vitro 
digestions 
natural response of 
memory CD8+ T cells from 








Text box 1 
Proteasome-mediated MHC-I-restricted antigen presentation pathway. 
The peptides presented at the cell surface on MHC-I molecules represent the immunopeptidome of 
the cell, which is specific to a given cell and it is influenced by several factors such as its MHC-I 
haplotype (each diploid human cell has six usually distinct MHC-I isoforms), and its intracellular 
proteome, i.e. the proteins expressed in the cell [71]. If an antigenic peptide bound to the MHC-I 
complex is recognized by TCRs of CD8+ T cells, it is defined as epitope. The large majority of the 
MHC-I-restricted antigenic peptides are produced in the proteasome chamber by canonical peptide-
bond hydrolysis or, as discussed here, by PCPS. These peptides can derive from rapidly degraded 
proteins (RDPs), which are supposed to include defective ribosomal products (DRiPs) and non-
exponentially degraded proteins (NEDPs), although the quantitative analysis of the 
immunopeptidome’s source is still a matter of debate [33, 64, 65, 71-73]. In the cytosol, the peptide 
fragments released from the proteasome are further degraded by aminopeptidases, thereby 
regenerating the cellular amino acids pool. Few of these peptides survive this step and are transported 
into the endoplasmic reticulum (ER) through a channel constituted by the transporters associated with 
antigen processing (TAPs). TAP-independent pathways, which are only partially proteasome-
dependent, have also been described [74, 75]. In the ER, the peptides are bound to the peptide-
loading complex, can be further trimmed by ER-resident aminopeptidases (ERAPs) and can finally 
bind the MHC-I complexes. The MHC-I-peptide complex undergoes modifications, and is transported 
through the Golgi to the cell surface. There, it is presented for a variable period of time, which 
depends in part on the affinity between the MHC-I complex and the peptide, as empty MHC-I 
molecules are rapidly recycled. At the cell surface, the MHC-I-peptide complex can be recognized by 
the TCR and CD8 of T cells, and, in presence of co-stimulatory factors (e.g. CD28, CD80, CD86), the 
binding induces the priming/activation of T cells [76]. 
 
Text box 2 
Proteasome isoforms and functions 
The 20S proteasome is the core of the ubiquitin-proteasome system (UPS), which is responsible for 
the degradation of the large majority of the cytosolic proteins. In eukaryotic cell, the complete inhibition 
of proteasome activity induces cell death through necrosis and apoptosis. Although there are 
evidences of the function of the 20S proteasome alone [77], this protease is often associated to 
regulatory particles such as 19S, PA28ab, PA28g, PA200, which affect proteasome conformation and 
activity [78-81].  Different 20S proteasome isoforms exist. The most common is the standard 
proteasome, whose catalytic activity is displayed by the Thr1 of the β1, β2 and β5 subunits. The 
proteasome in which these subunits are replaced by the β1i/LMP2, β2i/MECL1 and β5i/LMP7 subunits 
is named immunoproteasome and it is present in immune cells and when cells are exposed to an 
inflammatory milieu. Between the standard proteasome and immunoproteasome, there are also 
intermediate-type 20S proteasomes, which carry a different combination of standard- and immuno-
subunits [80]. Of note, cells generally contain a mixture of different 20S proteasome isoforms. In 2007, 
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a novel proteasome isoform has been identified, which is specific for the thymic cortex, i.e. the 
thymoproteasome, which carries the β1i, β2i and β5t subunits [3]. 
The effects of the changes in the catalytic subunit composition of standard proteasome and 
immunoproteasome have been studied by applying a large variety of methods, whereas for the 
thymoproteasome the research mainly focused so far on its role to determine the T cell repertoire in 
mice. 
The modifications of the catalytic subunits alter, of course, the catalytic pocket and thus the cleavage 
preferences but also they induce subtle modifications in the proteasome conformation, which affect 
proteasome proteolytic dynamics with consequences on protein turnover and on which and/or in which 
amount peptide products are produced [25, 29, 40, 41, 82-85].  





adoptive T cell therapies (ATTs): is a highly personalized cancer therapy that involves administration 
of T cells with direct anti-cancer activity to the cancer-bearing host [46]. 
 
BRAF: an isoform of RAF. RAF proteins are intermediate to Ras and MAPK in the cellular proliferative 
pathway. The BRAF V600E is the most common oncogenic mutation of BRAF in cancer. The mutation 
results in constitutive activation of the BRAF kinase and promotes cell transformation [87]. 
 
condensation reaction: in this review’s context, is a peptide splicing reaction catalyzed by 
proteasome, which does not need the initial peptide-bond cleavage (i.e. the step 1 in Fig. 1C). 
 
cortical thymic epithelial cells (cTECs): antigen presenting cells involved in the positive selection of 
the thymocytes in the cortical portion of the thymus. In mouse, they express mainly thymoproteasome, 
which has b1i, b2i, b5t as catalytic subunits [3]. 
 
fibroblast grow factor-5 (FGF-5): a secreted protein that is member of a family of heparin-binding 
growth factors. It regulates cell proliferation and it is overexpressed by multiple adenocarcinomas, 
thereby representing a tumor-associated antigen and a potential immunotherapy target. 
 
glycoprotein-100 (gp100): gp100, also known as melanocyte protein PMEL, is a tumor-associated 
antigen expressed by the majority of malignant melanomas. It has been shown to be immunogenic 
and elicits an antigen-specific CD8+ T cell response. It is currently used in anti-melanoma 
immunotherapy trials. 
 
KRAS: one of the Ras proteins, which are proto-oncogenes that are frequently mutated in human 
cancers. HRas, KRas, and NRas are GTPase that function as molecular switches in regulating 
pathways that are responsible for proliferation and cell survival. The KRAS G12D is a very frequent 
mutation in colon carcinomas and other cancers; it favors GTP binding and produces constitutive 
activation of Ras [88]. 
 
major histocompatibility complex class I (MHC-I): is the complex that presents epitopes to the TcR 
of CD8+ T cells the epitopes. The recognition of the MHC-I-epitope complex by the TcR of CD8+ T 
cells is the pre-requisite for the priming and/or activation of the CD8+ T cells (in presence of other co-
factors). The MHC-I complex is constituted of a molecule of b2-microglobulin and the MHC-I heavy 
chain, and is expressed by almost all cells but erythrocytes. 
 
phosphatidylcholine-preferring phospholipase C (PlcB): Listeria monocytogenes is a Gram-
positive bacterium that primarily infects phagocytes and then mobilizes the host cell cytoskeleton to 
spread to neighboring cells. To enter the cytosol of infected cells, the bacteria secrete LLO, the 
phospholipases PlcA/phosphatidylinositol-specific phospholipase C (PI-PLC) and 
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PlcB/phosphatidylcholine-preferring phospholipase C (PC-PLC). Bacterial clearance during L. 
monocytogenes infection is mediated by CD8+ T cells specific for the secreted bacterial proteins.   
 
tumor-infiltrating CD8+ T lymphocytes (TILs): are CD8+ T cells present in the tumor. TILs are one 
of the main source of T cells for ATTs. They can specifically recognize tumor-associated antigens and 
tumor-specific epitopes. 
 
proteasome-catalyzed peptide splicing (PCPS): the activity of proteasomes whereby two non-
contiguous fragments of a polypeptide substrate or a protein are ligated, thereby generating a spliced 
peptide with a sequence not present in the original protein. 
 
type 1 diabetes mellitus (T1DM): an autoimmune disease mediated by T cells responding to self 
antigens (e.g. proinsulin and islet amyloid polypeptide) in the pancreatic b cells of islets of 
Langherans. Both CD4+ and CD8+ T cell responses play a central role in the b cell destruction, which 






Which biochemical characteristics of proteasome catalytic sites favor PCPS efficiency so much more 
than expected? How are they altered by proteasome regulators such as 19S or PA28ab? 
 
Do tumor cells carry out PCPS as efficiently as lymphoblastoid B cells and primary human fibroblasts? 
 
Does cell infection affect proteasome dynamics and regulate PCPS efficiency? Can proteasome-
generated spliced epitopes derived from pathogens be as immunodominant as non-spliced epitopes? 
 
What is the frequency and abundance of proteasome-generated spliced epitopes at the cell surface of 
cTECs, mTECs and other professional antigen presenting cells involved in the positive/negative 
selection of thymocytes? How does the immune system cope with the larger antigen landscape 
generated by PCPS? Is the latter somehow related to the onset / development of any autoimmune 
response? 
 
Is it worth investing time and resources to identify spliced epitopes and target them through 
immunotherapies? 
 
Is PCPS relevant only for the MHC-I-restricted antigen presentation or does it have other functions 
either inside or outside the cell? 
 






The proteasome does not only cut proteins into fragments through canonical peptide-bond hydrolysis, 
but also ligates them through proteasome-catalyzed peptide splicing (PCPS). 
 
Through PCPS, the proteasome can significantly shape antigen presentation. This process is 
estimated to produce about one fourth of the antigenic peptide molecules and to enlarge the antigenic 
landscape - in term of antigenic peptide variety and antigens represented at the cell surface - by 
around 30%. 
 
PCPS is not a random process that ligates any fragment produced by proteasome. On the contrary, it 
seems to be finely tuned by driving forces that have been only preliminary investigated. 
 
Proteasome-generated spliced epitopes derived from tumor-associated antigens activate TILs, which 
in turn can reduce the tumor mass in patients and animal models. 
 
MHC-I and MHC-II immunopeptidomes contain other non-canonical peptides, which can play a special 
role in autoimmune diseases such as T1DM 
 



